The FDA’s March 2026 NAMs Guidance: A Strategic Framework for Reducing Animal Testing in Biotech
Executive Summary On March 18, 2026, the FDA issued a landmark draft guidance on New Approach Methodologies (NAMs), signaling a transformative shift in the preclinical landscape. For small biotechs, the guidance provides a formal pathway to use in silico models, organ-on-a-chip technology, and other non-animal methods to support regulatory decision-making. This is no longer just […]